Happiness is more than a mood; it’s “a state of well-being that encompasses living a good life, one with a sense of meaning and deep contentment.” It is a personal commitment to be optimistic even ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

When life unravels, we often grasp for anything to ease the pain. Some choices deepen our wounds, while others help us rebuild. Creativity can transform loss into resilience.

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single infusion of immunotherapy has kept patients healthy for more than five years.

Massage therapy can help lower blood pressure naturally, but the effects are short-term. Learn which types of massage can help with hypertension.

MSD has announced positive Phase III HYPERION trial results showing Winrevair (sotatercept-csrk) reduced clinical worsening events by 76% against placebo in recently diagnosed adults with pulmonary ...

Researchers report favorable safety and efficacy for a combination device after implantation and at 6 months follow-up among ICD candidates.

The U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify patients with advanced breast cancer that exhibit ESR1 mutations who may benefit ...

Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced positive interim results from its ongoing open-label clinical trial evaluating its ...

Opus Genetics today announced the positive 3-month pediatric data from its Phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber ...

A new study published in Social and Personality Psychology Compass has revealed that East Asian countries report lower average happiness than Western nations, not because they are poorer, but due to ...

The US Food and Drug Administration (FDA) has granted Nacuity Pharmaceuticals’ N-acetylcysteine amide tablets (NPI-001) breakthrough therapy designation.